drugset / Trial / NCT07615660
Clinical Study of CVL006 Combination With 9MW2821
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with 9MW821 patients with advanced solid tumors.
Timeline
- Start
- 2026-05-15
- Primary completion
- 2029-04-30
- Completion
- 2029-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 9MW2821 | Monoclonal antibody | 1.25 mg/kg | — |
| Subject | 9MW2821 | Monoclonal antibody | 1.5 mg/kg | — |
| Subject | CVL006 | Monoclonal antibody | 10 mg/kg | — |
| Subject | CVL006 | Monoclonal antibody | 20 mg/kg | — |